6 results on '"Goldberg, Jenna D."'
Search Results
2. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
- Author
-
Dreyling, Martin, Jurczak, Wojciech, Jerkeman, Mats, Silva, Rodrigo Santucci, Rusconi, Chiara, Trneny, Marek, Offner, Fritz, Caballero, Dolores, Joao, Cristina, Witzens-Harig, Mathias, Hess, Georg, Bence-Bruckler, Isabelle, Cho, Seok-Goo, Bothos, John, Goldberg, Jenna D, Enny, Christopher, Traina, Shana, Balasubramanian, Sriram, Bandyopadhyay, Nibedita, Sun, Steven, Vermeulen, Jessica, Rizo, Aleksandra, and Rule, Simon
- Subjects
MALIGNANCY ,CHRONIC LYMPHOCYTIC-LEUKEMIA ,BTK ,Medicine and Health Sciences ,SINGLE-AGENT TEMSIROLIMUS ,BORTEZOMIB ,PCI-32765 ,BRUTON TYROSINE KINASE ,FOLLOW-UP ,GUIDELINES ,THERAPY - Abstract
Background: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma. Methods: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index score, and were randomly assigned with a computer-generated randomisation schedule to receive daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent 21-day cycles). Randomisation was balanced by using randomly permuted blocks. The primary efficacy endpoint was progression-free survival assessed by a masked independent review committee with the primary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free survival. The analysis followed the intention-to-treat principle. The trial is ongoing and is registered with ClinicalTrials.gov (number NCT01646021) and with the EU Clinical Trials Register, EudraCT (number 2012-000601-74). Findings: Between Dec 10, 2012, and Nov 26, 2013, 280 patients were randomised to ibrutinib (n=139) or temsirolimus (n=141). Primary efficacy analysis showed significant improvement in progression-free survival (p
- Published
- 2016
3. Comparison of Outcomes at Two Institutions of Patients with Acute Lymphoblastic Leukemia Receiving Ex-Vivo T-Cell Depleted or Unmodified Allografts
- Author
-
Hobbs, Gabriela S., Hamdi, Amir, Hilden, Patrick D., Goldberg, Jenna D., Poon, Michelle L., Ledesma, Celina, Devlin, Sean M., Rondon, Gabriela, Papadopoulos, Esperanza B., Jakubowski, Ann A., O'Reilly, Richard J., Champlin, Richard E., Giralt, Sergio, Perales, Miguel-Angel, and Kebriaei, Partow
- Subjects
Adult ,Aged, 80 and over ,Male ,Transplantation Conditioning ,Adolescent ,T-Lymphocytes ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Allografts ,Models, Biological ,Article ,Disease-Free Survival ,Lymphocyte Depletion ,Survival Rate ,Humans ,Female ,Aged - Abstract
We compared outcomes of adult patients receiving T-cell depleted (TCD) hematopoietic stem cell transplantation (HCT) without additional GVHD prophylaxis at Memorial Sloan Kettering Cancer Center (MSKCC, N=52) with patients receiving conventional grafts at MD Anderson Cancer Center (MDACC, N=115) for acute lymphoblastic leukemia in CR1 or CR2. Patients received myeloablative conditioning. Thirty-nine patients received ATG at MSKCC and 29 at MDACC. Cumulative incidence of grades 2-4 acute (p=0.001, 17.3% vs. 42.6% at 100 days) and chronic GVHD (p=0.006, 13.5% vs. 33.4% at 3 years) were significantly lower in the TCD group. The NRM at day 100, 1 and 3 years was 15.4%, 25.0% and 35.9% in the TCD group and 9.6%, 23.6% and 28.6% in the unmodified group (p=0.368). There was no difference in relapse (p=0.107, 21.3% vs. 35.5% at 3 years), OS (p=0.854, 42.6% vs. 43.0% at 3 years), or RFS (p=0.653, 42.8% vs. 35.9% at 3 years). In an adjusted model, age >50, cytogenetics and CR status were associated with inferior RFS (HR=2.16, p=0.003, HR=1.77, p =0.022, HR=2.47, p
- Published
- 2015
4. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation – A Report from CIBMTR
- Author
-
Arai, Sally, Arora, Mukta, Wang, Tao, Spellman, Stephen R., He, Wensheng, Couriel, Daniel R., Urbano-Ispizua, Alvaro, Cutler, Corey S., Bacigalupo, Andrea A., Battiwalla, Minoo, Flowers, Mary E., Juckett, Mark B., Lee, Stephanie J., Loren, Alison W., Klumpp, Thomas R., Prockup, Susan E., Ringdén, Olle T.H., Savani, Bipin N., Socié, Gérard, Schultz, Kirk R., Spitzer, Thomas, Teshima, Takanori, Bredeson, Christopher N., Jacobsohn, David A., Hayashi, Robert J., Drobyski, William R., Frangoul, Haydar A., Akpek, Görgün, Ho, Vincent T., Lewis, Victor A., Gale, Robert Peter, DSc(hon), Koreth, John, Chao, Nelson J., Aljurf, Mahmoud D., Cooper, Brenda W., Laughlin, Mary J., Hsu, Jack W., Hematti, Peiman, Verdonck, Leo F., Solh, Melhelm M., Norkin, Maxim, Reddy, Vijay, Martino, Rodrigo, Gadalla, Shahinaz, Goldberg, Jenna D., McCarthy, Philip L., Pérez-Simón, José A., Khera, Nandita, Lewis, Ian D., Atsuta, Yoshiko, Olsson, Richard F., Saber, Wael, Waller, Edmund K., Blaise, Didier, Pidala, Joseph A., Martin, Paul J., Satwani, Prakash, Bornhäuser, Martin, Inamoto, Yoshihiro, Weisdorf, Daniel J., Horowitz, Mary M., and Pavletic, Steven Z.
- Subjects
Adult ,Male ,Adolescent ,International Cooperation ,Hematopoietic Stem Cell Transplantation ,Infant, Newborn ,Graft vs Host Disease ,Infant ,Middle Aged ,Myeloablative Agonists ,Survival Analysis ,Article ,Leukemia, Myeloid, Acute ,immune system diseases ,hemic and lymphatic diseases ,Child, Preschool ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Myelodysplastic Syndromes ,Chronic Disease ,Odds Ratio ,Humans ,Transplantation, Homologous ,Female ,Child ,Bone Marrow Transplantation - Abstract
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P.0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.
- Published
- 2014
5. A Phase 2 Study of a Non-myeloablative Allogeneic Stem Cell Transplant with Peri-transplant Rituximab in Patients with B-cell Lymphoid Malignancies: Favorably Durable Event-free Survival in Chemosensitive Patients
- Author
-
Sauter, Craig S., Barker, Juliet N., Lechner, Lauren, Zheng, Junting, Devlin, Sean M., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Jakubowski, Ann A., Goldberg, Jenna D., Koehne, Guenther, Ceberio, Izaskun, Giralt, Sergio, Zelenetz, Andrew D., Moskowitz, Craig H., and Castro-Malaspina, Hugo
- Subjects
Adult ,Male ,Lymphoma, B-Cell ,Transplantation Conditioning ,Graft vs Host Disease ,Antineoplastic Agents ,Article ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,hemic and lymphatic diseases ,Humans ,Transplantation, Homologous ,Prospective Studies ,Cyclophosphamide ,Aged ,Transplantation Chimera ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,Survival Analysis ,surgical procedures, operative ,Treatment Outcome ,Female ,Rituximab ,Unrelated Donors ,Vidarabine ,Whole-Body Irradiation - Abstract
The aim of this prospective phase II trial was to determine the safety and efficacy of a nonmyeloablative conditioning program incorporating peritransplant rituximab in patients with CD20+ B cell non-Hodgkin lymphoma (B-NHL) receiving an allogeneic stem cell transplant (allo-SCT). Fifty-one adult B-NHL patients, with a median age of 54 years, were treated with cyclophosphamide, fludarabine, and 200 cGy of total body irradiation. Rituximab 375 mg/m(2) was given on day -8 and in 4 weekly doses beginning day +21. Equine antithymocyte globulin was given to recipients of volunteer unrelated donor grafts. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil and tacrolimus, sirolimus, and methotrexate in 8 and 43 patients, respectively. Thirty-three patients received grafts from unrelated donors, and 18 received grafts from matched related donors. All patients engrafted. Full donor chimerism in bone marrow and peripheral T cells was seen in 92% and 89% of patients, respectively, at 3 months after allo-SCT. The cumulative incidence of grades II to IV acute GVHD at 6 months was 25% (95% confidence interval [CI], 13% to 38%) and grades III to IV was 11% (95% CI, 2% to 20%). The 2-year cumulative incidence of chronic GVHD was 29% (95% CI, 15% to 44%). The 2-year event-free and overall survival for all patients was 72% (95% CI, 59% to 85%) and 78% (95% CI, 66% to 90%), respectively. The 2-year event-free survival for chemosensitive patients was 84% (95% CI, 72% to 96%) compared with 30% (95% CI, 2% to 58%) for chemorefractory patients before allo-SCT (P.001). This nonmyeloablative regimen, with peritransplant rituximab, is safe and effective in patients with B-NHL.
- Published
- 2013
6. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in 1st complete remission with a decreased risk of graft-versus-host disease
- Author
-
Goldberg, Jenna D., Linker, Alex, Kuk, Deborah, Ratan, Ravin, Jurcic, Joseph, Barker, Juliet N., Castro-Malaspina, Hugo, Giralt, Sergio, Hsu, Katharine, Jakubowski, Ann A., Jenq, Robert, Koehne, Guenther, Papadopoulos, Esperanza B., van den Brink, Marcel R.M., Young, James W., Boulad, Farid, Kernan, Nancy A., O'Reilly, Richard J., Prockop, Susan E., Yahalom, Joachim, Heller, Glenn, and Perales, Miguel-Angel
- Subjects
Adult ,Male ,Adolescent ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Graft vs Host Disease ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Survival Analysis ,Article ,Disease-Free Survival ,Cohort Studies ,Young Adult ,surgical procedures, operative ,immune system diseases ,Recurrence ,Humans ,Female ,Retrospective Studies - Abstract
Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival benefit to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and relapse rates after T cell-depleted (TCD) allo-HSCT compared with unmodified transplantations for acute myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with significantly decreased graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy. The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% confidence interval [CI], 0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31), and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.